Other partially complementary messenger RNAs

Other partially complementary mRNAs refer to a broad class of transcripts that are unintentionally targeted by RNA-based therapeutics, such as small interfering RNAs (siRNAs) or antisense oligonucleotides (ASOs), due to partial sequence homology (Jackson et al., 2003, Nature Biotechnology). These interactions often occur via the 'seed region' of the siRNA (nucleotides 2-8), which can bind to the 3' untranslated regions (UTRs) of non-target mRNAs, leading to their degradation or translational inhibition in a manner similar to endogenous microRNAs (Birmingham et al., 2006, Nature Methods). This phenomenon is a primary driver of off-target toxicity in oligonucleotide drug development, as it can result in the suppression of essential genes not involved in the disease pathology (Setten et al., 2019, Nature Reviews Drug Discovery). Consequently, these mRNAs are not therapeutic targets but rather safety liabilities that must be minimized through chemical modifications, such as 2'-O-methyl substitutions, and rigorous sequence optimization. Bioinformatic tools are routinely employed to predict and avoid these partially complementary sequences to enhance the safety profile of RNAi and ASO candidates (Janowski et al., 2006, Nature Chemical Biology). Understanding the landscape of these unintended targets is crucial for biotech analysts evaluating the specificity and potential side-effect profile of novel RNA-targeting platforms.

Other names

Off-target mRNAsPartially matched transcriptsSeed-matched off-targetsNon-target mRNAsUnintended mRNA targets

Therapeutic oligonucleotides bind to these mRNAs via partial sequence complementarity, often mediated by the seed region, leading to unintended RNA-induced silencing complex (RISC) mediated degradation or translational repression (Jackson et al., 2003, Nature Biotechnology).